Yixintang Pharmaceutical Group Co., Ltd. (SHE:002727)
China flag China · Delayed Price · Currency is CNY
11.35
-0.49 (-4.14%)
Aug 27, 2026, 3:04 PM CST

SHE:002727 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Equivalents
2,5412,3023,4183,6763,5122,235
Short-Term Investments
---219.66--
Trading Asset Securities
925.75759.84--8.36297.3
Cash & Short-Term Investments
3,4663,0623,4183,8953,5202,532
Cash Growth
7.03%-10.40%-12.26%10.66%39.00%-17.16%
Accounts Receivable
1,4511,5631,6131,5551,7761,376
Other Receivables
269.11312.22319.49313.3307.29206.63
Receivables
1,7201,8751,9321,8682,0831,583
Inventory
3,4573,6734,0883,8533,3873,317
Prepaid Expenses
-1.033.491.030.140.16
Other Current Assets
349.79335.68270.29275.63467.06260.12
Total Current Assets
8,9938,9479,7129,8939,4587,692
Property, Plant & Equipment
3,2913,5743,9563,9513,9944,080
Long-Term Investments
140.21131.4136.52143.26352.46107.22
Goodwill
1,9651,9611,9831,6501,3971,380
Other Intangible Assets
288.89277.08196.86178.08165.67122.89
Long-Term Deferred Tax Assets
99.2102.0493.788.9494.1158.46
Long-Term Deferred Charges
484.73556.44724.03661.17629.9590.75
Other Long-Term Assets
46.0458.692982.3188.59305.71
Total Assets
15,30815,60816,83016,64716,17914,337

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Accounts Payable
4,3104,4364,9164,3394,3293,806
Accrued Expenses
223.73460.29539.54681.48518.75295.38
Short-Term Debt
567.67538.78503.76468.6402.57127.7
Current Portion of Long-Term Debt
826.95--1.80.24.02
Current Portion of Leases
-8511,005975.88932.771,012
Current Income Taxes Payable
124.9256.5653.6281.37197.86118.4
Current Unearned Revenue
123110.6116.9113.72156.61105.18
Other Current Liabilities
481.56411.2496.42537.55339.23415.09
Total Current Liabilities
6,6586,8647,6317,2006,8775,884
Long-Term Debt
8.8---1.835.08
Long-Term Leases
1,0031,2661,5311,5521,7571,729
Long-Term Unearned Revenue
27.2716.2911.5514.5412.1513.34
Long-Term Deferred Tax Liabilities
3.193.33.553.934.053.56
Total Liabilities
7,7008,1509,1778,7708,6527,665

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Common Stock
585.6585.6585.6596.01596.02596.18
Additional Paid-In Capital
2,0142,0132,0192,1442,1472,157
Retained Earnings
5,0054,8634,8865,0114,7003,869
Treasury Stock
-150-150--4.24-22.69-46.86
Comprehensive Income & Other
-8.06-8.55--6.192.93
Total Common Equity
7,4467,3037,4917,7467,4266,578
Minority Interest
162.13153.84162.27131.04101.4494.8
Shareholders' Equity
7,6087,4577,6537,8777,5286,673
Total Liabilities & Equity
15,30815,60816,83016,64716,17914,337

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Total Debt
2,4072,6563,0392,9983,0942,908
Net Cash (Debt)
1,060406.14378.39896.84425.94-375.58
Net Cash Growth
246.68%7.34%-57.81%110.56%--
Net Cash Per Share
1.860.700.641.500.72-0.63
Filing Date Shares Outstanding
-574.13585.6596.01596.02596.18
Total Common Shares Outstanding
-574.13585.6596.01596.02596.18
Working Capital
2,3352,0822,0802,6932,5811,809
Book Value Per Share
-12.7212.7913.0012.4611.03
Tangible Book Value
5,1925,0655,3115,9185,8635,075
Tangible Book Value Per Share
-8.829.079.939.848.51
Buildings
-916.42892.7894.92785.07741.03
Machinery
-465.66447.47416.9385.35350.85
Construction In Progress
-165.235.799.813.8725.47